This prospective study was performed to examine the safety and efficacy of a continuous infusion of ceftazidime in patients who developed febrile neutropenia after high-dose chemotherapy (HDCT) and autologous peripheral blood stem cell transplantation (PBSCT) and to determine if the underlying disease represents a risk factor for infectious complications. 
Infections due to severe neutropenia are a major cause of complications and mortality in patients treated with HDCT. The duration of neutropenia is the most important risk factor, but other factors can also alter the risk, 1 for example, chemotherapy-induced damage of the mucosa, indwelling central venous catheters, hypotension, altered mental status, age or underlying disease. Although there have been numerous reviews of infectious complications associated with allogenic bone marrow transplantation 2 only a few studies have dealt with infectious complications after autologous PBSCT. [3] [4] [5] Since the mid-1990s with the widespread use of blood progenitor cell transplantation there has been a need to redefine febrile neutropenia and its treatment. 6 Several studies have identified factors associated with favourable outcome if patients are treated on an outpatient basis. 7, 8 The aim of this prospective study was to determine whether the continuous infusion of ceftazidime followed, if necessary, by the addition of a glycopeptide antibiotic in neutropenic patients with persistent fever is adequate and safe as a first-line therapy. In addition, we wished to determine if the underlying disease has an impact on the risk and treatment strategy of infectious complications. A prime incentive for the study was that this approach would reduce the need for hospitalization of the patient and therefore could represent better use of health care resources.
Patients and methods

Patients
Eighty-seven patients with febrile neutropenia after HDCT and PBCT were included in the study: 55 with BC and 32 with MM. The median age of the BC group was 42 (range 22-59); the median age of the patients with MM was 52 (range 35-63). A neutrophil count of Ͻ500/l and fever Ͼ38.5°C not related to transfusion of blood products were the entry criteria for the study. Exclusion criteria were fever of non-infectious etiology and known intolerance to cephalosporin or glycopeptide antibiotics. Furthermore, patients with hypotension (syst Ͻ100 mm Hg) or Karnofsky index Ͻ60 were excluded. All patients stayed in an apartment or hotel near the hospital, and were examined daily by a physician and a nurse. The nurse monitored pulse, temperature and blood pressure, and administered fluid substitution or parenteral nutrition. Blood transfusions were ordered as necessary. No patients received any growth factor support after PBSCT.
All patients received oral antibiotic and antimycotic prophylaxis consisting of ciprofloxacin (2 ϫ 500 mg/day, n = 49), or levofloxacin (1 ϫ 500 mg/day, n = 38), and fluconazole (2 ϫ 200 mg/day, n = 51) or oral amphotericin B (n = 36). The prophylaxis was started on the first day of HDCT and continued until the beginning of systemic antibiotic treatment when the antibiotic prophylaxis was stopped and only the antimycotic was continued. 
Diagnostics at study entry
The initial work-up included a physical examination, and screening for an infectious focus. For the microbiological analysis, blood cultures were taken from peripheral veins as well as from the central venous catheter. In addition, urine cultures and swabs from suspicious skin lesions were taken and sputum was cultured if the patient was expectorating or had a pulmonary infiltrate. A chest X-ray was performed in each case. At the onset of fever (measured with an ear thermometer, First temp Genius; Sherwood Medical, Sulzbach, Germany) of more than 38.5°C, diagnostic procedures and antibiotic therapy were initiated immediately. An intravenous bolus of 2 g ceftazidime was given over 30 min followed by a 4 g continuous infusion over 24 h using a portable infusion pump (Walkmed Pump; Logomed, Oberursel, Germany). If the fever persisted for 72 h, teicoplanin (400 mg/day, n = 24 patients) or vancomycin (2 ϫ 1 g/day, n = 8 patients, infusion time 2 h) was initiated.
Classification of infections
FUO was considered in cases of temperature Ͼ38.5°C, with no clinically apparent source of infection, and negative cultures. Fever accompanied by clinical signs such as pulmonary infiltrates, skin or soft tissue infections, enteritis, perianal infection, catheter-related infection (CRI), or urinary tract infections were classified as CDI. Fever of confirmed bacterial or fungal etiology was classified as MDI. In cases of fever directly after transfusion of blood products antibiotic treatment was not initiated provided the fever resolved without specific therapy (ie within 1 or 2 h).
Treatment was classified as successful if fever resolved within 72 h and if the causative microorganisms were eradicated without any change of treatment.
Results
The results were analyzed in 87 patients with febrile neutropenia: 55 BC patients (group I: female n = 54, male n = 1) and 32 MM patients (group II: female n = 10, male n = 22).The patients' characteristics are summarized in Table 1 . The median, overall duration of neutropenia was 11 days in both groups (group I: range 7-17 days, group II: range 7-25 days). The duration of neutropenia after start of systemic antibiotic treatment was 8 days (range 1-13) in group I vs 7 days (range 3-18) in group II. The median Karnofsky score at the start of treatment was 70 in both groups (range 70-100). Thirty-five cases of febrile neutrop- enia in group I and 20 in group II responded to the monotherapy with ceftazidime. After addition of a glycopeptide antibiotic a further 11 patients in group I and 10 patients in group II became afebrile. In the nine failures of this initial antibiotic therapy in patients of group I and in the two patients of group II, ceftazidime was changed to imipenem/cilastin. In addition, in three patients systemic amphotericin B was started (one patient group I vs two patients group II; Table 2 ). There were no deaths among the treatment failures. In two MM patients a dose reduction of ceftazidime (2 g/24 h) was necessary because of renal insufficiency. One patient in each group developed an allergic exanthema of the skin due to the cephalosporin. MDI occurred in five of 55 patients in group I and eight of 32 patients in group II (Table 3) . One patient in group I and two patients in group II developed pneumonia. In addition, one of these patients had a central venous catheter infection with Staphylococcus aureus. The bacterium was found in a blood culture taken from a peripheral vein, and the same organism was detected on the catheter tip (Ͼ15 colony-forming units). Furthermore, the internal jugular vein was thrombosed in this patient. In one of the two patients of group II Aspergillus fumigatus was found in the sputum and radiological infiltrates typical for aspergillus pneumonia were detected. The fever and pulmonary infiltrates in this patient resolved after additional amphotericin B treatment and hematopoietic reconstitution. In the other patient, Streptococcus pneumoniae was found in the blood culture and the fever resolved on day 4 after start of antibiotic therapy. The pneumonia of the third patient improved on antibiotic therapy and systemic amphotericin B.
All Gram-negative (3/3) and 7/10 Gram-positive bacteria were sensitive to ceftazidime. All Gram-positive organisms were sensitive to the glycopeptide antibiotic. There were no confirmed cases of bacterial break-through infections during ceftazidime therapy. The patients in group I were Table 3 Cause of fever (Figures 1 and 2 ). Fourteen patients in group I and 10 patients in group II were admitted to hospital. The duration of outpatient treatment prior to hospital admission in group I was 7 days (range 5-10 days) and in group II 6 days (range 4-11 days). In one of three patients with Gram-negative and in seven of 10 patients with Gram-positive septicemia inpatient treatment was initiated. Also, two of three patients with pulmonary infiltrations were admitted to hospital. The reasons for inpatient treatment were: change of antimicrobial therapy (nine patients group I, two patients in group II), severe mucositis requiring full parenteral nutrition (four patients group I, four patients in group II) and Karnofsky score Ͻ60 (one patient in group I vs four patients in group II). In seven patients of group I and six patients of group II, outpatient treatment was resumed after a brief period of inpatient care. The average duration of inpatient treatment was 5 days (range 1-7) in group I and 6 days (range 1-18) in group II.
Discussion
Patients with neutropenia and fever constitute a heterogeneous group with varying risk profiles. 9,10 A prolonged period of neutropenia (more than 10 days), hypotension, severe mucositis, inadequate food intake, dehydration and altered mental status are recognized high-risk factors associated with life-threatening febrile neutropenia.
9,11,12 Talcott et al 10 showed that the complication rate in patients with fever and neutropenia was 34% if risk factors were present, and only 5% if they were absent.
In contrast to studies including patients with an expected neutropenia of Ͻ10 days, 8, 13, 14 we demonstrate that BC and MM patients up to the age of 63 years in stable clinical condition (Karnofsky у70 ) receiving HDCT with PBSCT who have febrile neutropenia lasting at least 10 days are candidates for outpatient treatment, independent of the underlying disease. The median duration of neutropenia was 11 days in both groups, of which 8 days (group I) vs 7 days (group II) were recorded after beginning of ceftazidime therapy.
As shown in Figures 1 and 2 , in neither group was there correlation between age and number of MDIs and CDIs, but a significantly higher number of MDIs and CDIs was found in group II compared to group I (31.12% vs 10.9%, P = 0.05).
These results are in line with those of Sezer et al. 4 In a retrospective study this group analysed the data from 100 consecutive adults with either malignant lymphoma or BC treated with high-dose chemotherapy at a single centre. Documented infections occurred in 30% of malignant lymphoma patients, but only in 4% of BC patients (P Ͻ 0.001).
The high response rate to antibiotic therapy we observed in both treatment groups was comparable with the results of other studies. 5, 15, 16 and much better than the results with ceftazidime plus glycopeptide reported in 1999 from our group. 3 The favourable response rate of Sezer et al 4 and the subsequent good results reported in 2000 from our group 5 could be explained by the high proportion of solid tumour patients in the study population. Thus, continuous infusion of ceftazidime is a reliable form for outpatient treatment due to the spectrum of activities especially against Gram-negative germs and the reliability of continuous infusion via infusion pump. 5 The predominant pathogens in our study were Grampositive (Table 4) . Low rates of pseudomonas infection in patients with fever and neutropenia have been reported since the 1980s, and with a continuous downward trend. 22 and indicates that close monitoring is necessary during the outpatient treatment. Eight of 13 MDIs and two of three CDIs were admitted to hospital but it was possible to treat one of three patients with proven Gram-negative infection, and three of 10 patients with proven Gram-positive infections in an outpatient setting, as well as one patient with pulmonary infiltration. In 63 patients, no inpatient treatment was necesarry; in these patients an average 20 (range 17-31) days per patient of hospital care were saved. In the other 24 patients an average of 10 (range 6-13) days in hospital were also avoided per patient.
17-
Several other studies have shown that in the absence of risk factors, patients with fever and neutropenia can be managed safely on an outpatient basis. 7, 8, 21 However, considerations relating to antibiotic bioavailability and tissue concentrations as well as patient compliance render treatment with some antibiotics unsuitable in an outpatient setting. 6, 8, 22 For example, deaths attributed to non-compliance with oral therapy have been reported by Malik et al. 8 The data from Kern et al 23 indicate that in low-risk patients an oral combination therapy consisting of ciprofloxacin plus amoxillin-clavulanate is as effective as ceftriaxone plus amicacin. However, patients were admitted to hospital in the latter multicentre trial.
Thus, in low-risk febrile neutropenic patients, outpatient antibiotic therapy is an alternative to inpatient treatment. 12 This approach can improve quality of life and, as has been demonstrated in the present study, is safe and effective in patients with BC and MM after HDCT and PBSCT. We do not recommend this procedure for older patients or patients autografted for leukemia. Moreover, the outpatient therapy is feasible only if the patients remain close to the hospital. For suitable patients, however, it can also represent a better use of health care resources.
